Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vfend- voriconazole · 1 trial · 1 indication
Percent of responders (by randomization strata) with success of antifungal prophylaxis at 180 days after allogeneic hematopoietic stem cell transplant (HSCT). Success: alive at Day 180 (Visit 9), had not developed a breakthrough proven or probable invasive fungal infection (IFI) by Visit 9, and received full course of study drug prophylaxis without interruption of greater than 14 days in total during the prophylaxis period; defined as failure if these criteria were not met. Additionally, if subject withdrew from study completely before Visit 9, imputed as failure at Visit 9 (programmatically).
| Arm | Type | Description |
|---|---|---|
| Itraconazole | ACTIVE_COMPARATOR | - |
| Voriconazole | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Itraconazole | DRUG | Prophylaxis |
| Vfend - voriconazole | DRUG | Prophylaxis |
Inclusion Criteria: * Allogeneic HSCT for acute leukemia (AML, ALL or myelodysplastic syndrome) failed lymphoma therapy or transformation of CML * Male and Female over 12 years or greater Exclusion Criteria: * Possible, probable or proven IFI at study entry or at any time in 6 months prior to stu...
Vfend (voriconazole) is used for antifungal prophylaxis of invasive fungal infections, specifically in patients undergoing allogeneic hematopoietic stem cell transplants. It is a small molecule developed by Pfizer, Inc. for the Infectious Disease therapeutic area.
Vfend (voriconazole) is developed by Pfizer, Inc., which trades under the ticker PFE. The drug is a small molecule intended for antifungal prophylaxis of invasive fungal infections.
Vfend (voriconazole) is in Phase 3 clinical development. It is an investigational drug for antifungal prophylaxis of invasive fungal infections and is not approved for this use based on the available data.
Vfend (voriconazole) has one completed Phase 3 trial, NCT00289991, which enrolled 489 participants. The trial compared voriconazole to itraconazole for primary prophylaxis of invasive fungal infection in subjects with allogeneic hematopoietic stem cell transplants.
Yes, Vfend is the brand name for voriconazole. The drug is referred to as Vfend (voriconazole) in clinical development, and the active ingredient is voriconazole.